NCT02529787View on ClinicalTrials.gov

A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2013

Study Completion Date

March 31, 2013

Conditions
Healthy
Interventions
DRUG

Doxirazole

1 capsule contains 60 mg Dexlansoprazole

DRUG

Dexilant

1 capsule contains 60 mg Dexlansoprazole

Trial Locations (1)

Unknown

Genuine Research Center GRC, Cairo

All Listed Sponsors
collaborator

Hikma Pharma,Egypt

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT02529787 - A Bioequivalence Study of Dexlansoprazole From Doxirazole 60 mg Capsules (Hikma Pharma,Egypt)and Dexilant 60 mg Delayed Release (DR) Capsules (Takeda Pharmaceuticals America Inc., USA) | Biotech Hunter | Biotech Hunter